{"id":"NCT00112047","sponsor":"Gilead Sciences","briefTitle":"Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects","officialTitle":"A Phase 3, Randomized, Multicenter Study of the Treatment of Antiretroviral-Naive HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs Combivir (Lamivudine/Zidovudine) and Efavirenz","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-07","primaryCompletion":"2005-02","completion":"2009-06","firstPosted":"2005-05-30","resultsPosted":"2010-10-13","lastUpdate":"2010-10-13"},"enrollment":517,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"Emtricitabine (FTC)","otherNames":["Emtriva"]},{"type":"DRUG","name":"Tenofovir Disoproxil Fumarate (TDF)","otherNames":["Viread"]},{"type":"DRUG","name":"Efavirenz (EFV)","otherNames":["Sustiva"]},{"type":"DRUG","name":"FTC/TDF","otherNames":["Truvada (TVD)"]},{"type":"DRUG","name":"FTC/TDF/EFV","otherNames":["Atripla (ATR)"]},{"type":"DRUG","name":"Lamivudine/zidovudine","otherNames":["Combivir (CBV)"]}],"arms":[{"label":"EFV+CBV","type":"ACTIVE_COMPARATOR"},{"label":"EFV+FTC+TDF","type":"EXPERIMENTAL"}],"summary":"The purpose of Study GS-01-934 was to assess the efficacy and safety of two simplified antiretroviral treatment (ART) regimens in ART-naive, human immunodeficiency virus, type 1 (HIV-1) infected participants. The primary objective of the study was to assess noninferiority of emtricitabine (FTC) and tenofovir disoproxil fumarate (tenofovir DF; TDF) in combination with efavirenz (EFV) relative to Combivir (CBV) in combination with EFV in the treatment of HIV-1 infected ART-naive participants, determined by the achievement and maintenance of confirmed HIV-1 ribonucleic acid (RNA) \\< 400 copies/mL (c/mL) through Week 48, as defined by the United States (US) Food and Drug Administration (FDA) time-to-loss-of-virologic-response (TLOVR) algorithm.","primaryOutcome":{"measure":"Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm","timeFrame":"48 weeks","effectByArm":[{"arm":"EFV+FTC+TDF","deltaMin":84.4,"sd":null},{"arm":"CBV+EFV","deltaMin":72.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":7},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["16421366"],"seeAlso":["http://www.Gilead.com","http://www.Viread.com","http://www.Sustiva.com","http://www.gileadclinicaltrials.com/pdf/GS-01-934_144_wk_synopsis.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":257},"commonTop":["Diarrhoea","Dizziness","Nausea","Nasopharyngitis","Upper Respiratory Tract Infection"]}}